• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Milestone Scientific Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    12/23/25 4:46:41 PM ET
    $MLSS
    Industrial Specialties
    Health Care
    Get the next $MLSS alert in real time by email
    false 0000855683 0000855683 2025-12-18 2025-12-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): December 18, 2025

     

    Milestone Scientific Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-14053   13-3545623

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    425 Eagle Rock Avenue, Suite 403

    Roseland, NJ

      07068

    (Address of principal executive offices)

     

    (Zip Code)

     

    Registrant’s telephone number, including area code (973) 535-2717

     

    N/A

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name on exchange on which registered
    Common Stock   MLSS   NYSE American

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 5.07 Submission of Matters to a Vote of Security Holders

     

    The 2024 Annual Meeting of Stockholders (the “Annual Meeting”) of Milestone Scientific Inc. (the “Company”) was held on December 18, 2025. At the Annual Meeting, the Company’s stockholders:

     

    ●Elected six incumbent directors to serve until the next annual meeting of the Company’s stockholders or until their respective successors have been duly elected and qualified;
      
    ●Approved an amendment to the Company’s Restated Certificate of Incorporation increasing the number of authorized shares of Common Stock from 100,000,000 to 125,000,000; and
      
    ●Ratified the appointment of CBIZCPA P.C. as the Company’s independent auditors for the fiscal year ending December 31, 2025.

     

    The total number of shares outstanding at the record date for the Annual Meeting was 78,628,913 shares of common stock. The total number of shares voted at the Annual Meeting was 48,381,413 shares of common stock, representing 61.53% of the issued and outstanding shares of common stock.

     

    The number of votes cast for, against or withheld and the number of abstentions and broker non-votes with respect to each Proposal is set forth below.

     

    PROPOSAL #001 ELECTION OF DIRECTORS INCLUDING DIRECTOR EXCEPTIONS

     

    ***   FOR   % VOTED FOR   WITHHELD   % VOTED WITHHELD
    BENEDETTA I. CASAMENTO   25,471,050   85.92%   4,173,862   14.08%
    NEAL GOLDMAN   26,283,035   88.66%   3,361,877   11.34%
    ERIC HINES   29,184,965   98.45%   459,947   1.55%
    DR. DIDIER DEMESMIN   25,788,621   86.99%   3,856,291   13.01%
    SHANTH THIYAGALINGAM   29,147,090   98.32%   497,822   1.68%
    DR. DAWOOD SAYED   29,264,979   98.72%   379,933   1.28%
    TOTAL ALL DIRECTORS   165,139,740       12,729,732    
    DIRECTOR AVERAGE   27,523,290       2,121,622    
    % VOTED OF AVERAGE   92.84%       7.16%    

     

    PROPOSAL #002 APPROVAL TO AMEND THE RESTATED CERTIFICATE OF INCORPORATION

     

    ***   FOR   AGAINST   ABS/WHD   BROKER NON-VOTES
    BENEFICIAL   42,491,824   1,845,895   26,055    
    REGISTERED   4,017,639   0   0    
    TOTAL SHARES VOTED   46,509,463   1,845,895   26,055    
    % OF VOTED   96.18%   3.81%        
    % OF OUTSTANDING   59.15%   2.34%        
    % OF VOTED W/ABS/WHD   96.13%   3.81%   0.05%    
    % OF OUTSTNDG W/ABS/WHD   59.15%   2.34%   0.03%    

     

    PROPOSAL #003 RATIFY CBIZ CPAS P.C. AS INDEPENDENT AUDITORS

     

    ***   FOR   AGAINST   ABS/WHD   BROKER NON-VOTES
    BENEFICIAL   43,580,300   542,809   240,665    
    REGISTERED   4,017,639   0   0    
    TOTAL SHARES VOTED   47,597,939   542,809   240,665    
    % OF VOTED   98.87%   1.12%        
    % OF OUTSTANDING   60.53%   0.69%        
    % OF VOTED W/ABS/WHD   98.38%   1.12%   0.49%    
    % OF OUTSTNDG W/ABS/WHD   60.53%   0.69%   0.30%    

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      Milestone Scientific Inc. 
         
    Dated: December 23, 2025 By: /s/ Eric Hines
        Eric Hines
        Chief Executive Officer

     

     

     

    Get the next $MLSS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MLSS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $MLSS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Scientific Launches CompuFlo® Advisor Program to Accelerate Commercial Adoption and Drive Utilization Growth in Select MAC Jurisdictions; Plans National Expansion

    ROSELAND, N.J., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide objective, pressure-guided precision, today announced the launch of the CompuFlo® Advisor Program. This strategic initiative is designed to drive mainstream commercial adoption, increase recurring disposable revenue, and generate the clinical data necessary to optimize long-term Medicare reimbursement rates. The program, which commenced on February 1, 2026, targets high-volume interventional pain and anesthesia practices within key Medicare Administrative Contractor (MAC) jurisdictions, including Novitas, First Coast, Noridian,

    2/23/26 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Launches The Wand® Ambassador Program to Expand Peer Engagement and Accelerate Market Adoption in Dentistry

    ROSELAND, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the launch of The Wand® Ambassador Program, a scalable peer-to-peer engagement initiative designed to expand clinical awareness, education, and adoption of The Wand® STA (Single Tooth Anesthesia®) System within the dental market. The program leverages experienced dental professionals to share real-world clinical insights, workflow considerations, and firsthand experiences with colleagues. This peer-driven approach is intended to increase high-quality engagement with prospective p

    1/6/26 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati

    11/13/25 4:00:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    SEC Filings

    View All

    Amendment: Milestone Scientific Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K/A - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    2/4/26 9:26:22 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    1/20/26 5:27:54 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - MILESTONE SCIENTIFIC INC. (0000855683) (Filer)

    12/23/25 4:46:41 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bp4 S.R.L. sold $84,884 worth of shares (194,427 units at $0.44), decreasing direct ownership by 2% to 8,896,765 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/29/25 4:29:34 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $28,472 worth of shares (64,034 units at $0.44), decreasing direct ownership by 0.70% to 9,091,192 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/23/25 4:49:27 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Large owner Bp4 S.R.L. sold $27,273 worth of shares (50,158 units at $0.54), decreasing direct ownership by 0.44% to 9,155,226 units (SEC Form 4)

    4 - MILESTONE SCIENTIFIC INC. (0000855683) (Issuer)

    10/17/25 4:39:17 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Financials

    Live finance-specific insights

    View All

    Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company's transformation and growth initiatives. Eric Hines, Chief Executive Officer of Milestone Scientific, stated, "During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operati

    11/13/25 4:00:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Schedules Third Quarter 2025 Financial Results and Business Update Conference Call

    ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today announced that it will host a conference call at 8:30 AM Eastern Time on Friday, November 14th, 2025, to discuss the company's financial results for the third quarter ended September 30, 2025, as well as the company's corporate progress and other developments. The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 164353. A webcast and replay of the call may be acc

    11/13/25 2:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Achieves 25% Increase in Revenue for the Second Quarter of 2025

    ROSELAND, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provides a business update and reported financial results for the second quarter ended June 30, 2025. Neal Goldman, Chairman of the Board, stated, "We are pleased with our revenue performance in the second quarter, delivering a 25% increase in revenue to $2.3 million, driven by strong international dental sales, which more than doubled year-over-year. We also maintained a strong gross margin of 70%, reflecting the benefits of our high-margin dental business and disciplined cost management.

    8/14/25 4:15:00 PM ET
    $MLSS
    Industrial Specialties
    Health Care

    $MLSS
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Scientific Appoints Dr. Dawood Sayed to Board of Directors to Advance Commercial and Clinical Strategy in Pain Management

    ROSELAND, N.J., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Dawood Sayed, M.D., a nationally recognized leader in interventional pain medicine, to its Board of Directors, effective immediately. Dr. Sayed is a Professor of Anesthesiology and Pain Medicine at the University of Kansas Medical Center and currently serves as Division Chief of Pain Medicine, Director of Interventional Spine Services, and Director of the Center for Neuromodulation. With a robust clinical, academic, and policy background, he brings over a deca

    9/22/25 9:15:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Jason Papes as Senior Vice President, Global Head of Sales and Marketing

    ROSELAND. N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Jason Papes as Senior Vice President, Global Head of Sales and Marketing, effective immediately. Mr. Papes brings more than three decades of experience in sales, marketing, and business development within the healthcare industry, including leadership roles at large-cap medical technology companies and successful entrepreneurial ventures. His expertise spans orthopedics, neurology, pain management, and digital imaging, with a track record of building high-perfor

    8/6/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care

    Milestone Scientific Appoints Eric C. Hines as Chief Executive Officer

    ROSELAND, N.J., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced the appointment of Eric C. Hines as Chief Executive Officer, effective immediately. Mr. Hines brings more than 25 years of leadership experience in scaling sales-driven enterprise software companies, serving customers across a range of industries, including healthcare. Most recently, he served as President of North America at Ex Libris, a division of Clarivate, where he led operations across the U.S., Canada, and Latin America and increased annual revenue from approximately $50 m

    8/1/25 8:30:00 AM ET
    $MLSS
    Industrial Specialties
    Health Care